Aion Therapeutic (XCNQ:AION) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is Aion Therapeutic Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Aion Therapeutic is: No Data: Cannot be evaluated.

Competitive Comparison of Aion Therapeutic's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aion Therapeutic's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Aion Therapeutic (XCNQ:AION) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Aion Therapeutic Risk Assessment Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Aion Therapeutic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (XCNQ:AION) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

ANTCF:USA

Address

700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8

Website

https://www.aiontherapeutic.com

Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.

Executives

Ismail Abdul Fattah	Director or Senior Officer of 10% Security Holder
Douglas Craig Wilson	Director or Senior Officer of 10% Security Holder
John Graham Simmonds	Director, Senior Officer

Aion Therapeutic Headlines

No Headlines